The DNMBP Knockout 786-O Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human 786-O renal cell carcinoma line, featuring targeted disruption of the DNMBP gene. This stable loss-of-function model provides a robust genetic background for investigating DNMBP-dependent cellular processes without the drawbacks of transient knockdown methods.
The 786-O cell line originates from a primary clear cell renal adenocarcinoma and is widely utilized as a model for renal cell carcinoma research. It harbors a characteristic VHL gene mutation, leading to constitutive hypoxia-inducible factor activation, and maintains an adherent epithelial phenotype. These features render 786-O cells well-suited for studies of tumor cell migration, invasion, and therapeutic resistance, as well as for drug screening applications.
DNMBP functions as a scaffold protein that bridges actin cytoskeleton dynamics and membrane remodeling at cell?Ccell junctions. It directly interacts with dynamin-2, cortactin, syndapin, and F-actin, thereby coupling clathrin-mediated endocytosis to cortactin-driven Arp2/3 complex activation and branched actin polymerization. Acting downstream of Rho GTPases including RhoA and Rac1, DNMBP reinforces tight junction integrity by tethering ZO-1/occludin complexes to the actin network. Furthermore, DNMBP intersects with the Wnt pathway, potentially modulating ??-catenin/TCF/LEF transcriptional responses through its roles in endocytic trafficking and junctional stability. This integrative scaffolding activity places DNMBP at a key regulatory nexus for epithelial polarity and cell migration.
In the 786-O cellular context, DNMBP ablation is anticipated to impair epithelial barrier function, reshape cortical actin organization, and enhance motility and invasiveness??hallmarks of renal cell carcinoma progression. Additionally, disruption of DNMBP-mediated endocytosis may alter the surface abundance and recycling of growth factor receptors, thereby modifying cellular sensitivity to mTOR inhibitors and other targeted therapeutics used in kidney cancer treatment.
These polyclonal knockout cells are suitable for a wide array of applications, including dissection of tight junction permeability, endocytic trafficking, and cell adhesion dynamics. They support experimental techniques such as Western blotting for DNMBP and junctional markers, immunofluorescence localization of tight junctions, wound healing and Transwell migration assays, transferrin uptake quantification, co?immunoprecipitation of DNMBP with dynamin?2 and cortactin, RT?qPCR profiling, apoptosis analysis, and drug sensitivity testing with mTOR inhibitors. For detailed technical inquiries or assay customization, please contact Ascent Research.
